Literature DB >> 23697486

The crisis in access to essential medicines in India: key issues which call for action.

Anurag Bhargava1, S P Kalantri.   

Abstract

The government is planning to introduce free generic and essential medicines in public health facilities. Most people in India buy healthcare from the private sector, a compulsion that accounts for a high proportion of healthcare-related expenditure. To reduce the burden of healthcare costs, the government must improve availability and affordability of generic and essential medicines in the market. It can do so because India's large pharmaceutical industry is a major source of generic medicines worldwide. In this article, we discuss three factors that have impeded access to generic and essential medicines: (1) mistaken notions among policymakers, prescribers and patients about branded drugs and generic drugs in India; (2) high prices of medicines due to the progressive dismantling of the system of regulation of medicine prices, and (3) a drug approval and regulatory system that allows medicines (including fixed dose combinations) of doubtful efficacy, rationale, safety and public health relevance to dominate the market at the cost of access to affordable generic and essential medicines. The consequences of ill-health and wasted expenditure on drugs raise issues of public health ethics.Improving access to essential medicines in India is an urgent public health and ethical imperative. This should include improved public provisioning, a system of regulation of drug prices, and an evidence-based drug approval process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23697486     DOI: 10.20529/IJME.2013.028

Source DB:  PubMed          Journal:  Indian J Med Ethics        ISSN: 0974-8466


  8 in total

1.  Assessment of e-aushadhi program (drug inventory e-health initiative in Rajasthan) using benefit evaluation framework.

Authors:  Neha Mantri; Nitin K Joshi; Pankaj Bhardwaj; Balwant Manda; Vibha Joshi; Kuldeep Singh; Rakesh Passi
Journal:  J Family Med Prim Care       Date:  2022-05-14

2.  Catastrophic health expenditure on private sector pharmaceuticals: a cross-sectional analysis from the state of Odisha, India.

Authors:  Annie Haakenstad; Anuska Kalita; Bijetri Bose; Jan E Cooper; Winnie Yip
Journal:  Health Policy Plan       Date:  2022-08-03       Impact factor: 3.547

3.  Availability of Pediatric Formulations in Public Health Care System in India: A Case Study.

Authors:  Vandana Roy; Shubha Singhal; Himanshu Tayal; A P Dubey
Journal:  Indian J Pediatr       Date:  2020-02-21       Impact factor: 1.967

4.  Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries.

Authors:  Deepali Sharma; Rahul P Patel; Syed Tabish R Zaidi; Md Moklesur Rahman Sarker; Qi Ying Lean; Long C Ming
Journal:  Front Pharmacol       Date:  2017-08-21       Impact factor: 5.810

5.  A Cost Analysis of the Jan Aushadhi Scheme in India.

Authors:  Kanchan Mukherjee
Journal:  Int J Health Policy Manag       Date:  2017-05-01

6.  Perceptions of the quality of generic medicines: implications for trust in public services within the local health system in Tumkur, India.

Authors:  Praveen Kumar Aivalli; Maya Annie Elias; Manoj Kumar Pati; Srinath Bhanuprakash; Chikkagollahalli Munegowda; Zubin Cyrus Shroff; Prashanth N Srinivas
Journal:  BMJ Glob Health       Date:  2018-01-13

7.  Generic drugs: Review and experiences from South India.

Authors:  Philip Mathew
Journal:  J Family Med Prim Care       Date:  2015 Jul-Sep

8.  Assessment of current prescribing practices using World Health Organization core drug use and complementary indicators in selected rural community pharmacies in Southern India.

Authors:  Anandhasayanam Aravamuthan; Mohanavalli Arputhavanan; Kannan Subramaniam; Sam Johnson Udaya Chander J
Journal:  J Pharm Policy Pract       Date:  2016-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.